| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051567 | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Aug, 2019
(4 years ago) | |
| US6274169 | ABBVIE | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Aug, 2019
(4 years ago) | |
| US6265392 | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Aug, 2019
(4 years ago) | |
|
US6265392 (Pediatric) | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Feb, 2020
(4 years ago) | |
|
US6274169 (Pediatric) | ABBVIE | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Feb, 2020
(4 years ago) | |
|
US6051567 (Pediatric) | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Feb, 2020
(4 years ago) | |
Calcijex is owned by Abbvie.
Calcijex contains Calcitriol.
Calcijex has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Calcijex are:
- US6051567
- US6274169
- US6265392
- US6265392*PED
- US6274169*PED
- US6051567*PED
Calcijex was authorised for market use on 25 September, 1986.
Calcijex is available in injectable;injection dosage forms.
The generics of Calcijex are possible to be released after 02 February, 2020.
Drugs and Companies using CALCITRIOL ingredient
Market Authorisation Date: 25 September, 1986
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of CALCIJEX before it's drug patent expiration?
More Information on Dosage
CALCIJEX family patents
